Biological Products, (No Diagnostic Substances) · DE · CIK 875045
Biogen discovers, develops, and delivers innovative therapies for serious and complex diseases, focusing on neurology, immunology, and rare diseases
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article · skews ▼ negative.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Feb 12, 2026: 1 insider bought $585 · 1 sold $666K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Murphy NicoleHead of Pharm Ops and Tech | Buy | 3 | $195.04 | $585 |
| Feb 9, 2026 | Singhal PriyaHead of Development | Sell | 2,660 | $199.83 | $532K |
| Feb 2, 2026 | Singhal PriyaHead of Development | Sell | 748 | $179.30 | $134K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.